imiquimod has been researched along with ovalbumin in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (35.29) | 29.6817 |
| 2010's | 11 (64.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Imbertson, LM; Stanczak, TL; Tomai, MA; Tygrett, LT; Waldschmidt, TJ | 1 |
| Brett, SJ; Daly, MG; Thomsen, LL; Tite, JP; Topley, P | 1 |
| Bystryn, JC; Johnston, D | 1 |
| Bian, T; De, W; Hu, JJ; Jin, SX; Ma, XQ; Yin, KS; Zhang, XL; Zhou, JY | 1 |
| Hennessy, T; Hook, S; McBurney, WT; Myschik, J; Rades, T | 1 |
| Daugimont, L; Lecouturier, N; Préat, V; Richiardi, H; Ucakar, B; Vanderhaeghen, ML; Vandermeulen, G | 1 |
| Aranda, F; Bezunartea, J; Borrás-Cuesta, F; Díaz-Valdés, N; Durantez, M; Lasarte, JJ; Llopiz, D; Mansilla, C; Martínez, M; Prieto, J; Riezu-Boj, JI; Ruiz, M; Sarobe, P | 1 |
| Gogoll, K; Langguth, P; Radsak, M; Schild, H; Stein, P; Wei, H | 1 |
| Berger, CM; Dang, Y; Disis, ML; Gad, E; Holt, GE; Rastetter, L; Wagner, WM | 1 |
| Boyd, BJ; Hanley, T; Hook, S; McBurney, WT; Rades, T; Rizwan, SB; Young, K | 1 |
| Gogoll, K; Langguth, P; Radsak, MP; Schild, H; Stein, P; Stevanovic, S; Tenzer, S | 1 |
| Chen, X; Jia, J; Liu, Q; Liu, Y; Ma, G; Wang, L; Yang, T; Zhang, W | 1 |
| Bialojan, A; Denny, M; Langguth, P; Lopez, PA; Probst, HC; Radsak, MP; Rausch, J; Schild, H | 1 |
| Li, P; Li, Y; Lu, C; Ren, S; Wang, Q; Zhang, Y | 1 |
| Burton, SA; Chu, LY; Hansen, KJ; Niu, L; Panyam, J | 1 |
| Aranda Lopez, P; Bialojan, A; Denny, M; Hartmann, AK; Langguth, P; Probst, HC; Radsak, MP; Rausch, J; Schild, H; Sohl, J; Yagita, H | 1 |
| Azam, T; Beckman, K; de Graaf, DM; Dinarello, CA; Fischer, S; Fujita, M; Højen, JF; Kristensen, MLV; Lunding, LP; McKee, AS; Swartzwelter, BJ; Tolstrup, M; Wade, MT; Wegmann, M | 1 |
17 other study(ies) available for imiquimod and ovalbumin
| Article | Year |
|---|---|
The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes.
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Antibody Specificity; Antigens, CD; B-Lymphocytes; B7-2 Antigen; Cells, Cultured; Guanosine; Humans; Imidazoles; Imiquimod; Immunoglobulin Class Switching; Immunoglobulin E; Immunoglobulin G; Lipopolysaccharides; Lymphocyte Activation; Membrane Glycoproteins; Mice; Mice, Inbred Strains; Ovalbumin; Spleen | 2000 |
Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery.
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Biolistics; CD11 Antigens; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cytokines; Imidazoles; Imiquimod; Immunization; Immunotherapy; Injections, Subcutaneous; Interferon-gamma; Lymph Nodes; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Microspheres; Ovalbumin; Plasmids; Th1 Cells; Vaccines, DNA | 2004 |
Topical imiquimod is a potent adjuvant to a weakly-immunogenic protein prototype vaccine.
Topics: Adjuvants, Immunologic; Administration, Topical; Aminoquinolines; Animals; Antibodies; Antibody Formation; CD8-Positive T-Lymphocytes; Enzyme-Linked Immunosorbent Assay; Female; Imiquimod; Immunoglobulin G; Immunoglobulin M; Injections, Subcutaneous; Interferons; Mice; Mice, Inbred C57BL; Ovalbumin; Vaccination; Vaccines | 2006 |
Treatment of allergic airway inflammation and hyperresponsiveness by imiquimod modulating transcription factors T-bet and GATA-3.
Topics: Administration, Inhalation; Aminoquinolines; Animals; Asthma; Bronchi; Bronchial Hyperreactivity; Cytokines; Eosinophils; GATA3 Transcription Factor; Gene Expression Regulation; Imiquimod; Lung; Male; Ovalbumin; Rats; Rats, Sprague-Dawley; RNA, Messenger; T-Box Domain Proteins; Transcription Factors | 2006 |
Immunogenicity of lipid sustained release implants containing imiquimod, alpha-galactosylceramide, or Quil-A.
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Antineoplastic Agents; CD8-Positive T-Lymphocytes; Delayed-Action Preparations; Drug Carriers; Drug Implants; Epitopes; Flow Cytometry; Galactosylceramides; Imiquimod; Immunization; Immunoglobulin G; Lipids; Mice; Mice, Inbred C57BL; Microscopy, Electron, Transmission; Organisms, Genetically Modified; Ovalbumin; Quillaja Saponins; Saponins; Vaccines | 2008 |
Effect of tape stripping and adjuvants on immune response after intradermal DNA electroporation.
Topics: Adjuvants, Immunologic; Administration, Cutaneous; Aminoquinolines; Animals; Antibody Formation; Electroporation; Female; Hyaluronoglucosaminidase; Imiquimod; Immunization; Immunoglobulin G; Lipid A; Luciferases; Mice; Mice, Inbred BALB C; Ovalbumin; Plasmids; Vaccines, DNA | 2009 |
Adjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumors.
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Antibodies; Antibody Affinity; Antigens, Neoplasm; CD4 Antigens; Female; Imiquimod; Immunity, Innate; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Ovalbumin; Poly I-C; T-Lymphocytes; Thymoma; Transfection | 2011 |
Comparative transcutaneous immunization with imiquimod-containing ointments and potential of in vitro methods to predict effects.
Topics: Adjuvants, Immunologic; Administration, Cutaneous; Aminoquinolines; Animals; Antigens; Imiquimod; Mice; Mice, Inbred C57BL; Models, Biological; Ointments; Ovalbumin; Peptide Fragments; Permeability; Rheology; Skin Absorption | 2012 |
Dendritic cell-activating vaccine adjuvants differ in the ability to elicit antitumor immunity due to an adjuvant-specific induction of immunosuppressive cells.
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Cancer Vaccines; Dendritic Cells; Granulocyte-Macrophage Colony-Stimulating Factor; Imiquimod; Immunosuppression Therapy; Insulin-Like Growth Factor Binding Protein 2; Interferon Inducers; Mice; Mice, Transgenic; Myeloid Cells; Ovalbumin; Toll-Like Receptor 7 | 2012 |
Cubosomes containing the adjuvants imiquimod and monophosphoryl lipid A stimulate robust cellular and humoral immune responses.
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Antigens; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Drug Delivery Systems; Female; Imiquimod; Immunity, Cellular; Immunity, Humoral; Lipid A; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Nanostructures; Ovalbumin; Vaccines | 2013 |
Efficacy of imiquimod-based transcutaneous immunization using a nano-dispersed emulsion gel formulation.
Topics: Adjuvants, Immunologic; Administration, Cutaneous; Aminoquinolines; Animals; Cancer Vaccines; Cell Line, Tumor; Emulsions; Female; Gels; Imiquimod; Male; Mice, Inbred C57BL; Neoplasm Transplantation; Ovalbumin; Peptide Fragments; Skin Absorption; T-Lymphocytes, Cytotoxic; Thymoma; Vaccination | 2014 |
Immunopotentiator-Loaded Polymeric Microparticles as Robust Adjuvant to Improve Vaccine Efficacy.
Topics: Adjuvants, Immunologic; Adjuvants, Pharmaceutic; Aminoquinolines; Animals; Antigens; Female; Imiquimod; Immunity, Cellular; Immunoglobulin G; Influenza A Virus, H5N1 Subtype; Lactic Acid; Male; Mice; Mice, Inbred C57BL; Ovalbumin; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Vaccines | 2015 |
Combined immunotherapy: CTLA-4 blockade potentiates anti-tumor response induced by transcutaneous immunization.
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Antineoplastic Agents, Immunological; CTLA-4 Antigen; Drug Synergism; Flow Cytometry; Humans; Imiquimod; Immunologic Memory; Immunotherapy; Melanoma, Experimental; Membrane Glycoproteins; Mice; Mice, Inbred C57BL; Ovalbumin; Peptide Fragments; Skin Neoplasms; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Toll-Like Receptor 7; Xenograft Model Antitumor Assays | 2017 |
[Imiquimod combined with dendritic cell vaccine decreases Treg proportion and enhances anti-tumor responses in mice bearing melanoma].
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Cancer Vaccines; Dendritic Cells; Granulocyte-Macrophage Colony-Stimulating Factor; Imiquimod; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Ovalbumin; T-Lymphocytes, Regulatory; Toll-Like Receptor 7 | 2017 |
Intradermal delivery of vaccine nanoparticles using hollow microneedle array generates enhanced and balanced immune response.
Topics: Adjuvants, Immunologic; Animals; Antigens; Delayed-Action Preparations; Dendritic Cells; Imiquimod; Immunoglobulin G; Injections, Intradermal; Lipid A; Lymph Nodes; Mice, Inbred C57BL; Microinjections; Nanoparticles; Needles; Ovalbumin; Rats; Toll-Like Receptor 7; Vaccines | 2019 |
Transcutaneous immunization with CD40 ligation boosts cytotoxic T lymphocyte mediated antitumor immunity independent of CD4 helper cells in mice.
Topics: Administration, Cutaneous; Allografts; Animals; CD27 Ligand; CD40 Ligand; Cytotoxicity, Immunologic; Gene Expression; Graft Rejection; Imiquimod; Immunization; Immunologic Memory; Immunotherapy; Melanoma, Experimental; Membrane Glycoproteins; Mice; Mice, Inbred C57BL; Ovalbumin; Skin; Skin Neoplasms; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Helper-Inducer; Toll-Like Receptor 7 | 2019 |
IL-1R3 blockade broadly attenuates the functions of six members of the IL-1 family, revealing their contribution to models of disease.
Topics: A549 Cells; Animals; Antibodies, Blocking; Antibodies, Monoclonal; Cell Line, Tumor; Disease Models, Animal; HEK293 Cells; Humans; Imiquimod; Inflammation; Interleukin-1; Interleukin-1 Receptor Accessory Protein; Interleukin-1beta; Interleukin-33; Male; Mice; Mice, Inbred C57BL; Ovalbumin; Peritonitis; Pneumonia; Psoriasis; Signal Transduction; Uric Acid | 2019 |